{"title": null, "author": null, "url": null, "hostname": null, "description": "Revista Finlay", "sitename": null, "date": "2023-03-24", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|Cuba registr\u00f3 la primera vacuna terap\u00e9utica contra el c\u00e1ncer de pulm\u00f3n avanzado en el mundo, nombrada CIMAVAX-EGF, con la cual han recibido tratamiento m\u00e1s de 1 000 pacientes en la isla, anunci\u00f3 hoy el semanario \u00abTrabajadores\u00bb, report\u00f3 CubaDebate.\n|\nLa responsable del proyecto de esta vacuna en el Centro de Inmunolog\u00eda Molecular (CIM) de La Habana, Gisela Gonz\u00e1lez, explic\u00f3 que ofrece la posibilidad de convertir el c\u00e1ncer avanzado en una \u00abenfermedad cr\u00f3nica controlable\u00bb.\nCIMAVAX-EGF es resultado de m\u00e1s de quince a\u00f1os de investigaci\u00f3n, va dirigida hacia el sistema relacionado con el tumor y no provoca efectos adversos severos, precis\u00f3 la especialista.\n\u00abEst\u00e1 basada en una prote\u00edna que todos tenemos: el factor de crecimiento epid\u00e9rmico, relacionado con los procesos de proliferaci\u00f3n celular, que cuando hay c\u00e1ncer est\u00e1n descontrolados\u00bb, detall\u00f3.\nGonz\u00e1lez indic\u00f3 que como el organismo tolera \u00ablo propio\u00bb y reacciona contra \u00ablo extra\u00f1o\u00bb, por eso tuvieron que hacer \u00abuna composici\u00f3n tal que lograra generar anticuerpos contra esta prote\u00edna\u00bb.\nEsta vacuna se aplica en el momento en el que el paciente concluye el tratamiento con radioterapias o quimioterapias y es considerada \u201cterminal sin alternativa terap\u00e9utica\u201d porque ayuda a \u201ccontrolar el crecimiento del tumor sin toxicidad asociada, precis\u00f3.\nAdem\u00e1s, puede ser utilizada como un tratamiento \u00abcr\u00f3nico que aumenta las expectativas y la calidad de vida del paciente\u00bb.\nLa investigadora se\u00f1al\u00f3 que despu\u00e9s de alcanzar su registro en Cuba, actualmente el CIMAVAX-EGF \u00abprogresa\u00bb en otros pa\u00edses y que se eval\u00faa la forma de emplear su principio en terapias contra otros tumores como los de pr\u00f3stata, \u00fatero y mamas.\nFINLAY EN:\nFINLAY CERTIFICADA POR:\nEsta revista \"no aplica\" cargos por publicaci\u00f3n en ninguna etapa del proceso editorial.\nDirecci\u00f3n postal: Calle 51A y Avenida 5 de Septiembre Cienfuegos, Cuba C\u00f3digo postal: 55100.\n[http://www.revfinlay.sld.cu]\nTelefono: +53 43 516602. Telefax: +53 43 517733.\n[amgiraldoni@infomed.sld.cu](mailto:amgiraldoni@infomed.sld.cu)\nISSN: 2221-2434\nRNPS: 5129", "language": null, "image": null, "pagetype": null, "links": ["https://revfinlay.sld.cu/index.php/finlay/information/readers", "https://revfinlay.sld.cu/index.php/finlay/information/authors", "https://revfinlay.sld.cu/index.php/finlay/information/librarians", "https://revfinlay.sld.cu/index.php/finlay/article/view/1214", "https://revfinlay.sld.cu/index.php/finlay/article/view/1206", "https://revfinlay.sld.cu/index.php/finlay/article/view/1235", "https://revfinlay.sld.cu/index.php/finlay/article/view/1255", "https://revfinlay.sld.cu/index.php/finlay/article/view/1232", "https://revfinlay.sld.cu/index.php/finlay/article/view/164", "https://revfinlay.sld.cu/index.php/finlay/article/view/403", "https://revfinlay.sld.cu/index.php/finlay/article/view/39", "https://revfinlay.sld.cu/index.php/finlay/article/view/242", "https://revfinlay.sld.cu/index.php/finlay/article/view/253", "https://revfinlay.sld.cu/index.php/finlay/issue/current/showToc", "https://revfinlay.sld.cu/index.php/finlay/MedisurNavigationPlugin/viewFutureIssue", "https://revfinlay.sld.cu/index.php/finlay/issue/archive", "https://revfinlay.sld.cu/index.php/finlay/search/authors", "https://revfinlay.sld.cu/index.php/finlay/search/titles", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/AnnouncementFeedGatewayPlugin/atom", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/AnnouncementFeedGatewayPlugin/rss2", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/AnnouncementFeedGatewayPlugin/rss", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/WebFeedGatewayPlugin/atom", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/WebFeedGatewayPlugin/rss2", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/WebFeedGatewayPlugin/rss", "https://revfinlay.sld.cu/index.php/finlay/search?subject=accidente%20cerebrovascular", "https://revfinlay.sld.cu/index.php/finlay/search?subject=adolescente", "https://revfinlay.sld.cu/index.php/finlay/search?subject=adulto", "https://revfinlay.sld.cu/index.php/finlay/search?subject=anciano", "https://revfinlay.sld.cu/index.php/finlay/search?subject=atenci%C3%B3n%20primaria%20de%20salud", "https://revfinlay.sld.cu/index.php/finlay/search?subject=cuba", "https://revfinlay.sld.cu/index.php/finlay/search?subject=diabetes%20mellitus", "https://revfinlay.sld.cu/index.php/finlay/search?subject=diabetes%20mellitus%20tipo%202", "https://revfinlay.sld.cu/index.php/finlay/search?subject=diagn%C3%B3stico", "https://revfinlay.sld.cu/index.php/finlay/search?subject=enfermedad%20cr%C3%B3nica", "https://revfinlay.sld.cu/index.php/finlay/search?subject=enfermedades%20cardiovasculares", "https://revfinlay.sld.cu/index.php/finlay/search?subject=factores%20de%20riesgo", "https://revfinlay.sld.cu/index.php/finlay/search?subject=hipertensi%C3%B3n", "https://revfinlay.sld.cu/index.php/finlay/search?subject=informes%20de%20casos", "https://revfinlay.sld.cu/index.php/finlay/search?subject=morbilidad", "https://revfinlay.sld.cu/index.php/finlay/search?subject=mortalidad", "https://revfinlay.sld.cu/index.php/finlay/search?subject=neoplasias%20de%20la%20mama", "https://revfinlay.sld.cu/index.php/finlay/search?subject=obesidad", "https://revfinlay.sld.cu/index.php/finlay/search?subject=prevenci%C3%B3n%20de%20enfermedades", "https://revfinlay.sld.cu/index.php/finlay/search?subject=reporte%20de%20casos", "https://revfinlay.sld.cu/index.php/finlay/search?subject=terap%C3%A9utica", "https://revfinlay.sld.cu/index.php/finlay/index", "https://revfinlay.sld.cu/index.php/finlay/about", "https://revfinlay.sld.cu/index.php/finlay/login", "https://revfinlay.sld.cu/index.php/finlay/user/register", "https://revfinlay.sld.cu/index.php/finlay/search", "https://revfinlay.sld.cu/index.php/finlay/issue/current", "https://revfinlay.sld.cu/index.php/finlay/issue/archive", "https://revfinlay.sld.cu/index.php/finlay/announcement", "http://www.revfinlay.sld.cu/index.php/finlay/about/submissions#onlineSubmissions", "https://revfinlay.sld.cu/index.php/finlay/index", "https://revfinlay.sld.cu/index.php/finlay/announcement", "https://revfinlay.sld.cu/index.php/finlay/announcement/view/39", "http://scholar.google.com.cu/scholar?hl=es&q=Revista+Finlay&btnG=Buscar&lr=&as_sdt=0%2C5", "http://www.doaj.org/doaj?func=openurl&issn=22212434&genre=journal&uiLanguage=en", "http://www.bvscuba.sld.cu/php/level.php?lang=es&component=56&item=63", "http://www.latindex.unam.mx/buscador/ficRev.html?opcion=1&folio=20073", "http://new.medigraphic.com/cgi-bin/publicaciones.cgi?IDREVISTA=294", "http://extranet.who.int/hinari/es/browse_journal_titles.php?j_init=F", "http://scielo.sld.cu/scielo.php?script=sci_serial&pid=2221-2434&lng=es&nrm=iso", "https://www.redib.org/recursos/Serials/Record/oai_revista1086-finlay", "http://science.thomsonreuters.com/cgi-bin/jrnlst/jlresults.cgi?PC=EX&ISSN=2221-2434", "https://www.facebook.com/Finlay-Revista-de-Enfermedades-Cr%C3%B3nicas-320153004349/", "https://twitter.com/revfinlay", "/index.php/finlay/about/editorialTeam", null, "mailto:amgiraldoni@infomed.sld.cu"]}